Publications

Scientific Presentations

Stevens RM, Guedes K, Mistry N, Tiseo P, Lascelles D, Campbell J, Mendoza M, Ball D. Efficacy of Bilateral Intra-articular CNTX-4975 Injection for Management of Painful Knee Osteoarthritis. https://www.fsipp-conference.com/pdf/FSIPP%202019%20Educational%20Guide.pdf

The Florida Society of Interventional Pain Physician (FSIPP)

View Abstract

Stevens RM, Guedes K, Mistry N, Tiseo P, Lascelles D, Campbell J, Mendoza M, Ball D. Assessment of cooling methods for reducing procedural pain associated with CNTX-4975 injection for management of painful knee osteoarthritis. https://www.fsipp-conference.com/pdf/FSIPP%202019%20Educational%20Guide.pdf

The Florida Society of Interventional Pain Physician (FSIPP)

View Abstract

Stevens R, Guedes K, Mistry N, Lascelles D, Ball D. Intra-articular CNTX-4975 for painful knee osteoarthritis: assessment of cooling methods for reducing procedural pain. Ann Rheum Dis. 2019;78(suppl 2). http://dx.doi.org/10.1136/annrheumdis-2019-eular.1156

European League Against Rheumatism (EULAR)

View Abstract

Stevens R, Guedes K, Armas E, Smith V, Volosov A. Pharmacokinetics (PK) of a single intra-articular (IA) injection of CNTX-4975 (trans-capsaicin) vs topical 8% capsaicin patch. Ann Rheum Dis. 2019;78(suppl 2). http://dx.doi.org/10.1136/annrheumdis-2019-eular.5941

European League Against Rheumatism (EULAR)

View Abstract

Campbell J, Stevens RM, Hanson PD. Characterization of the pharmacology and pharmacokinetics of CNTX-4975, a high-purity, synthetic trans-capsaicin in clinical development for the treatment of moderate to severe OA knee pain [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/characterization-of-the-pharmacology-and-pharmacokinetics-of-cntx-4975-a-high-purity-synthetic-trans-capsaicin-in-clinical-development-for-the-treatment-of-moderate-to-severe-oa-knee-pain/

American College of Rheumatology (ACR)

View Abstract

Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. http://ard.bmj.com/content/76/Suppl_2/121.2

European League Against Rheumatism (EULAR)

View Abstract

Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: a 24-week, randomized, double-blind, placebo-controlled, dose-ranging study. http://www.tandfonline.com/doi/abs/10.1080/00325481.2017.1367065

PAINWeek

View Abstract

Stevens R, Petersen D, Ervin J, Nezzer J, Nieves Y, Campbell J, Guedes K, Burges R, Hanson P. Efficacy and safety of CNTX-4975 in subjects with moderate to severe osteoarthritis knee pain: 24-week, randomized, double-blind, placebo-controlled, dose-ranging study [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). http://acrabstracts.org/abstract/efficacy-and-safety-of-cntx-4975-in-subjects-with-moderate-to-severe-osteoarthritis-knee-pain-24-week-randomized-double-blind-placebo-controlled-dose-ranging-study/

American College of Rheumatology (ACR)

View Abstract

Stevens R, Simons G, Brand T, Hettema W, Corradini L, Pollenter S. Phase 1 study of the safety and tolerability of single ascending doses of the novel oral CCR2 antagonist CNTX-6970 in healthy volunteers [abstract]. Pain Med. 2018;19(4). doi.org/10.1093/pm/pny044 Published by Oxford University Press on behalf of the American Academy of Pain Medicine. Please visit: https://academic.oup.com/painmedicine/article/19/4/818/4954176

American Academy of Pain Medicine (AAPM)

View Abstract